Navigation Links
FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
Date:1/25/2012

erythema, flaking/scaling, crusting and swelling. 

"LEO Pharma is committed to helping people achieve healthy skin. We are pleased to introduce Picato® gel, a new treatment option for patients with actinic keratosis, a common precancerous condition," said John Koconis, President and CEO, LEO Pharma Inc. "The approval of Picato® gel in the United States is another step forward in helping us realize our vision of becoming a preferred dermatology care partner worldwide."   

For more information about Picato® gel, including full prescribing information, please visit www.leo-pharma.us/home/products/LEO-pharma-products.aspx.

About Actinic Keratosis
Actinic keratosis (AK) is a dry, scaly, rough-textured patch or lesion that forms on the outermost layer of the skin after cumulative exposure to ultraviolet (UV) light, such as sunlight. In some cases, the lesions may be easier to feel than see. The name actinic keratosis literally means "sun-induced rough spot" and therefore the lesions, which can be gray, pink, red or the same color as the skin, are often called sun spots and/or age spots.

A job that requires spending hours of time outside, or everyday activities such as gardening, exercise or attending outdoor sporting events, can lead to sun damage if skin isn't adequately protected. People at high risk are often fair-skinned men and women over the age of 40 who may have accumulated a significant amount of sun exposure over the course of many years.[1]

About Picato® (ingenol mebutate) gel, 0.015%, 0.05%
Picato® gel is indicated for the topical treatment of actinic keratosis.

To date, 18 clinical trials have been completed for the use of Picato® gel, from phase I trials through pivotal phase III trials. In phase III clinical trials, 60-68 percent of patients with actinic k
'/>"/>

SOURCE LEO Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... WOONSOCKET, R.I. , Aug. 21, 2014 CVS ... early tender results, applicable Reference Yields and consideration payable in ... Offers") commenced on August 7, 2014 for (1) any and ... and All Notes") and (2) up to a maximum amount ... due 2041 and 5.750% Senior Notes due 2017 (collectively, the ...
Breaking Medicine Technology:Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... American Corporate Health, was recently recognized as ... professionals in the field of workers’ compensation. ... Workers’ Compensation and Occupational Medicine Conference was ... attorneys, physicians, nurses, case managers, disability specialists, ...
(Date:8/21/2014)... As part of a continuing mission to ... joined with the Alliance for Safe Online Pharmacies (ASOP) ... sale of medicines. , “Helping to ensure the quality, ... a core mission for USP and an important tool ... T. Piervincenzi, chief executive officer of USP. “The illegal ...
(Date:8/21/2014)... 21, 2014 According to a new ... Optics Market-Global Industry Analysis, Size, Share, Growth, Trends and ... market was valued at USD 863.1 million in 2013 ... 7.6% from 2013 to 2019, to reach an estimated ... medical fiber optics market is witnessing significant growth due ...
(Date:8/21/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... valued at USD 236.1 million in 2011 and is ... in 2018 at a CAGR of 6.3% from 2012 ... Report: http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The worlds ... offer customers an exciting chance to grab free products. ... all-natural deodorant from Tom's of Maine with all qualifying ... deodorant and our environmentally friendly yoga apparel is simply ... The joint promotion between the two brands is intended ...
Breaking Medicine News(10 mins):Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2
... and Company) (NYSE: BDX ), a global medical ... Bear Stearns 20th Annual,Healthcare Conference on Monday, September 10, ... of BD,s presentation can be accessed from the BD,corporate ... for replay,through Monday, September 17, 2007. BD, a ...
... Pa., Aug. 30 As part of his work,to ... health,insurance, Governor Edward G. Rendell today said 35,000 uninsured,individuals ... Insurance,Program will be given the opportunity to receive health ... insurance brings a sense of security and peace of ...
... pathway in the most common and aggressive type of ... to fuel tumor growth and help cancers evade drug ... In a series of laboratory and animal experiments, Johns ... with an experimental compound called cyclopamine to explore the ...
... reduce or prevent allergic reactions, group suggests , THURSDAY, ... people with seasonal allergies may suffer oral allergy syndrome ... pollen proteins from weeds, grass and trees and similar ... symptoms of OAS -- also known as pollen-food syndrome ...
... The sort of swelling that occurs when a joint ... the healing process, but when it comes to the knee, ... findings in experiments with pigs may lead to treatments for ... Medical Center orthopedic researchers. There are drugs that can block ...
... with the respiratory condition , , WEDNESDAY, Aug. 29 (HealthDay ... guidelines Wednesday that seek to make breathing easier and ... the lung disease. , "Asthma control is achievable for ... the National Heart, Lung, and Blood Institute, said during ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2Health News:New insights into common knee injuries 2Health News:New Asthma Guidelines Stress Disease Control 2Health News:New Asthma Guidelines Stress Disease Control 3
For the quantitative determination of Glycohemoglobin in blood....
For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
... storage protein for iron. The ferritin molecule ... of heavy and light subunits, which surrounds ... phosphate [1]. Ferritin is synthesized in the ... with major concentrations found in the liver, ...
Rapid turn-around time, results in less than 4 hours...
Medicine Products: